AVR

Business Context and Reporting Period

Company: Anteris Technologies Global Corp. (AVR)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and six months ended June 30, 2025
Business Overview: Anteris is a structural heart company developing the DurAVR® THV system, a single-piece biomimetic heart valve for treating aortic stenosis. The company operates as a single segment focused on the development and commercialization of its ADAPT® anti-calcification tissue technology. Following a reverse recapitalization and IPO in late 2024, the company is currently in the pre-commercialization phase, preparing for the PARADIGM pivotal clinical trial.

Key Financial Metrics

Note: Q2 2024 data is presented for comparison; 6M 2024 cash balance is from the end of that period.

Material Changes vs. Prior Period

• Revenue Decline: Net sales decreased 16% year-over-year for the six months ended June 30, 2025 ($1.17M vs. $1.40M). This is primarily due to the expiration of the Transition Services Agreement with LeMaitre in January 2025, which previously generated sales of CardioCel® and VascuCel® products.
• Increased R&D Spend: Research and development expenses rose 36% for the six months ended June 30, 2025 ($32.8M vs. $24.2M). The increase is driven by upscaling manufacturing capabilities, quality validation, headcount expansion, and preparatory activities for the PARADIGM clinical trial.
• Reduced SG&A: Selling, general, and administrative expenses decreased 16% for the six-month period ($10.7M vs. $12.7M), attributed to lower share-based compensation and marketing spend, offsetting increased compliance costs related to dual listing requirements.
• Cash Burn: Net cash used in operating activities increased 42% to $41.0 million for the six months ended June 30, 2025, compared to $28.9 million in the prior year period.

Outlook, Risks, and Management Commentary

• Clinical Trial Progress: The company has qualified 79 sites for the PARADIGM Trial across the U.S., Europe, and Canada. Enrollment is anticipated to begin in the third quarter of 2025, pending FDA Investigational Device Exemption (IDE) approval.
• Going Concern: The filing explicitly states that recurring losses and cash outflows raise substantial doubt about the company's ability to continue as a going concern for one year from the issuance date. Management believes the going concern basis is appropriate but acknowledges the need for additional capital.
• Liquidity Needs: As of June 30, 2025, cash balances were $28.4 million. Management does not believe current cash on hand will fund operations for the next 12 months and intends to raise additional funds through equity or debt offerings.
• Internal Controls: The company disclosed material weaknesses in internal control over financial reporting related to a lack of documented procedures and deficiencies in segregation of duties. These remain unremediated as of June 30, 2025.
• Revenue Outlook: Significant revenue is not expected until regulatory approvals (FDA PMA and CE Mark) are obtained and commercial sales commence.

Investor Verification Checklist

• Cash Runway: Verify the timeline for the next capital raise given the explicit "substantial doubt" regarding going concern status and a cash balance of $28.4M against a $41M operating burn rate for six months.
• PARADIGM Trial Timeline: Confirm the status of the FDA IDE application and the actual start date of patient enrollment, as this is the critical path to commercialization.
• Revenue Concentration: Note that revenue is currently derived almost entirely from legacy tissue products (4C Medical Technologies), with the primary customer accounting for 75% of six-month revenue. Verify the sustainability of this revenue stream post-transition.
• Internal Control Remediation: Monitor progress on remediation of material weaknesses in financial reporting, which could impact future filing reliability.
• Debt Obligations: Review the terms of the $0.4M supplier financing arrangements for insurance premiums to ensure no immediate covenant risks exist.